Does UnitedHealthcare Cover Cialis (Tadalafil)?

What Formulary Tier Is Cialis on UnitedHealthcare?

Cialis (tadalafil) sits on Tier 3 on most UnitedHealthcare commercial PPO and HMO formularies, meaning you pay a higher copay or coinsurance than you would for a generic. Exact cost-sharing depends on your specific plan document. Always pull your Summary of Benefits and Coverage (SBC) or call the number on the back of your insurance card before filling a prescription.

The FDA approved tadalafil for erectile dysfunction in 2003 and for BPH in 2011, giving it a long regulatory track record [1]. UHC's coverage policy reflects those approved indications. Tadalafil works by inhibiting phosphodiesterase type 5 (PDE5), increasing cyclic GMP and relaxing smooth muscle in the corpus cavernosum and the bladder outlet [2]. Because the mechanism is well characterized, payers generally cover it under a medical-necessity standard rather than a lifestyle exclusion, provided the diagnosis code is documented correctly.

Generic tadalafil has been available since 2018 and typically occupies Tier 1 or Tier 2 on UHC formularies, substantially reducing out-of-pocket cost [3]. If your prescriber writes for "tadalafil" rather than "Cialis," the pharmacy will dispense the generic by default in most states, and your cost may drop to $20 to $30 per month even with insurance.

The FDA label specifies the 5 mg once-daily dose for BPH and the 2.5 mg, 5 mg, 10 mg, and 20 mg doses for ED [4]. Aligning the prescription with the labeled dose matters because payer systems flag off-label dose requests for additional review.

What Are UnitedHealthcare's Prior Authorization Criteria for Cialis?

Prior authorization for Cialis on UHC commercial plans is rated moderate difficulty and focuses on three clinical checkpoints: confirmed diagnosis, trial of a preferred agent, and absence of contraindications. PA approval is not guaranteed, but meeting all three criteria substantially raises the approval rate.

UHC's published clinical criteria align with the American Urological Association (AUA) guideline on ED, which identifies PDE5 inhibitors as first-line pharmacotherapy [5]. The AUA states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction in appropriately selected patients" [5]. Your prescriber's PA submission should reference this guideline directly.

Typical UHC PA requirements for tadalafil include:

1. A documented diagnosis of ED (ICD-10 N52.x) or BPH (N40.1) in the medical record.
2. Confirmation that cardiovascular contraindications have been evaluated. Tadalafil is contraindicated with nitrates; the prescriber must attest this has been assessed [4].
3. On plans with step therapy, proof that the patient tried sildenafil (or another covered PDE5 inhibitor) for at least 30 days and either failed to respond or experienced a documented adverse effect [6].

The prescriber submits the PA through UHC's Provider Portal or by fax using the specific form listed in the UHC Drug Coverage Policies database. Processing time is generally 2 to 3 business days for standard requests and 24 hours for urgent requests under federal parity rules [7]. A clinical pharmacist review, not an automated denial, is standard for Tier 3 medications.

Clinical trial data support the medical-necessity argument. Brock et al. (J Urol, 2003, N=1,112) demonstrated that tadalafil 20 mg produced statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score versus placebo (P<0.001), with 75% of intercourse attempts successful compared with 32% in the placebo group [8]. Submitting this evidence level alongside the PA can strengthen the case.

For BPH, a key 12-week RCT (N=325) showed tadalafil 5 mg once daily reduced International Prostate Symptom Score (IPSS) by 5.6 points versus 2.3 points with placebo (P<0.001) [9]. Payers typically find symptom-scale data compelling when reviewing BPH PA requests.

Does UnitedHealthcare Require Step Therapy Before Approving Cialis?

Many UHC commercial plans impose step therapy, requiring a trial of at least one other PDE5 inhibitor before Cialis is approved. Sildenafil (generic Viagra) is the most commonly required step because it is Tier 1 on most UHC formularies and carries a significantly lower cost to the plan.

Step therapy typically means a 30-day trial. If sildenafil is ineffective or produces intolerable side effects (most commonly headache, flushing, or visual disturbances), the prescriber documents the failure in writing and resubmits the PA for tadalafil. Side-effect profiles differ between agents; tadalafil's longer half-life of approximately 17.5 hours versus sildenafil's 3 to 5 hours is clinically meaningful for patients who prefer spontaneity [10].

Some patients qualify for step-therapy exceptions immediately. The AUA guideline and several state-level step-therapy protection laws allow bypassing the step when a clinical contraindication to the required agent exists, when the patient has already tried and failed the required agent, or when a prior authorization approval for the requested drug was in place during the previous plan year [5]. At least 27 states had enacted step-therapy protection legislation as of 2024 [11]. Confirm whether your state's law applies to your specific plan type; self-insured employer plans governed by ERISA may not be covered by state mandates.

How Do I Appeal a UnitedHealthcare Denial of Cialis?

A denial is not final. UHC's appeal process has two internal levels followed by access to an external independent review organization (IRO). Most appeals that include complete clinical documentation are resolved within 30 days.

Level 1 Internal Appeal. Submit within 180 days of receiving the denial notice. Include the denial letter, a letter of medical necessity from the prescriber, relevant office visit notes, and any peer-reviewed evidence supporting the use of tadalafil for the specific indication. The AUA guideline [5] and the Brock et al. trial data [8] are two primary sources worth attaching. UHC must respond within 30 days for pre-service appeals and 60 days for post-service appeals under the ACA's internal appeals requirements [12].

Level 2 Internal Appeal. If Level 1 is denied, request a second review within the timeframe specified in the denial letter. At this stage, ask for a peer-to-peer conversation between your prescriber and the UHC medical director. Prescriber-to-prescriber conversations resolve a meaningful proportion of Level 2 denials without proceeding further.

External IRO Review. If both internal levels fail, you have the right to request an external review through a state-certified or federally certified IRO. The IRO decision is binding on UHC. Under federal rules, the IRO must issue a decision within 45 days for standard requests and 72 hours for expedited urgent requests [12]. The IRO applies an independent clinical standard, not UHC's internal criteria, which can work in the patient's favor.

The HealthRX clinical team developed the following decision framework for patients facing a UHC tadalafil denial. Step 1: confirm the denial reason code (not-medically-necessary vs. step-therapy vs. non-formulary). Step 2: match the denial code to the correct rebuttal document. Step 3: submit Level 1 with at minimum the AUA guideline citation, the prescriber's clinical note, and the specific trial failure documentation. Step 4: if denied again, request peer-to-peer within 5 business days. Step 5: file for external IRO review with the original clinical package plus any updated literature.

The FDA's enforcement discretion does not extend to insurance denials, so the appeal pathway is the only regulatory remedy short of litigation [13].

What Does Cialis Cost Without UnitedHealthcare Coverage?

If coverage is denied or your plan excludes tadalafil entirely, out-of-pocket costs vary widely by source. Brand Cialis carries a list price of approximately $450 per month, which is rarely what anyone actually pays. Generic tadalafil is the practical alternative.

GoodRx and similar pharmacy discount services price generic tadalafil 5 mg at roughly $20 to $35 per 30-tablet supply at major chains as of mid-2025. The 20 mg as-needed tablets price similarly per unit. These prices are not insurance and cannot be combined with insurance in the same transaction, but they undercut many insurance copays for Tier 3 drugs [3].

The Eli Lilly manufacturer savings card (Lilly Cares program) offers commercially insured patients a reduced copay, sometimes as low as $25 per month, for brand Cialis. This card is explicitly not valid for patients enrolled in Medicare, Medicaid, or any other federal or state government-funded program [14]. Confirm eligibility on the Lilly website before presenting the card at the pharmacy.

Telehealth platforms, including HealthRX, can prescribe generic tadalafil as part of a supervised treatment plan. Compounded tadalafil is available from 503A compounding pharmacies at lower price points, though the FDA has noted that compounded drugs are not FDA-approved and may vary in potency and purity [13]. Prescribers should discuss this distinction with patients choosing the compounding route.

Does UnitedHealthcare Cover Daily-Dose Tadalafil Differently Than As-Needed Tadalafil?

The coverage pathway is the same, but the clinical justification differs. Daily tadalafil 5 mg is FDA-approved for both ED and BPH, so a single prescription can address two diagnoses simultaneously in eligible patients [4]. Payers sometimes request clarification when a 5 mg daily dose is submitted with an ED-only diagnosis, because 5 mg is the lower end of the ED dosing range and is also the BPH dose. Specifying both ICD-10 codes (N52.x and N40.1) when both conditions are present prevents unnecessary PA delays.

A 24-week RCT published in the Journal of Urology (N=1,058) found that tadalafil 5 mg once daily significantly improved both IPSS and IIEF scores in men with both BPH and ED, compared to placebo, with a mean IIEF-EF domain score increase of 5.0 points (P<0.001) [15]. Dual-indication prescriptions backed by this data are generally more defensible in PA and appeal submissions.

Medicare Part D plans follow a different coverage framework. Most Medicare Part D formularies exclude drugs used "for the treatment of sexual or erectile dysfunction" under the statutory exclusion in the Social Security Act, unless the drug is also approved for another indication covered by Part D [16]. Tadalafil 5 mg for BPH can sometimes be covered under Part D when the BPH diagnosis is the primary indication and the prescriber codes accordingly.

How to Get UnitedHealthcare to Approve Tadalafil: A Step-by-Step Checklist

Preparing a complete submission upfront reduces the back-and-forth that delays approval by days or weeks. The following checklist reflects standard UHC commercial PA requirements.

• Confirm the correct ICD-10 code: N52.9 (ED, unspecified), N52.01 (vasculogenic ED), or N40.1 (BPH with LUTS) as appropriate.
• Include an office visit note dated within 12 months documenting the diagnosis and clinical findings.
• Document cardiovascular risk assessment and confirm no concurrent nitrate use (contraindication per FDA label [4]).
• If step therapy applies, attach written documentation of the sildenafil trial: dates used, dose, duration, and reason for discontinuation.
• Attach the AUA ED Guideline (2018, amended 2024) citation [5] and at least one RCT (Brock et al. [8] or the IPSS/IIEF dual-indication trial [15]).
• Submit through UHC Provider Portal for the fastest processing; fax adds 24 to 48 hours.
• Request a receipt or tracking number. Follow up by phone after 48 hours if no decision has been issued.
• If denied, note the specific denial reason and initiate Level 1 appeal within 180 days.

The prescriber's clinical documentation is the single most modifiable factor in whether a PA succeeds. A note that says "patient requests Cialis" carries far less weight than a note that reads "patient failed sildenafil 50 mg for 8 weeks due to visual disturbances; tadalafil requested per AUA guideline first-line recommendation."

Does UnitedHealthcare Cover Tadalafil for Pulmonary Arterial Hypertension?

Yes, but under a different pathway. Tadalafil 40 mg (brand name Adcirca, now generic) is FDA-approved for pulmonary arterial hypertension (PAH) and is covered under a separate UHC medical policy for PAH management [17]. The coverage criteria for PAH tadalafil are more rigorous, typically requiring specialist documentation (pulmonology or cardiology), hemodynamic confirmation of PAH, and failure or contraindication to endothelin receptor antagonist therapy in some plans. This article focuses on the ED and BPH indications; patients seeking PAH coverage should work with their pulmonologist to manage the distinct PA pathway.

A landmark trial, PHIRST (N=405), showed that tadalafil 40 mg once daily reduced the risk of clinical worsening by 38% compared with placebo (P<0.01) in WHO Functional Class II and III PAH patients, supporting the medical-necessity argument for this indication [18].